Sign In
Buy HOTH
$0.792
+0.0013 (+0.164%)
At Close: Jul 31, 2026
Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery
10:03am, Thursday, 05'th Oct 2023
The new wholly owned subsidiary will screen for rare disease therapeutics. NEW YORK , Oct. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company,
FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients
08:33am, Monday, 02'nd Oct 2023
NEW YORK , Oct. 2, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the Pre-IND meeting requested on September 8 th for HT-KI
Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
02:38pm, Friday, 15'th Sep 2023
NEW YORK , Sept. 15, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) ("Hoth" or the "Company"), a patient-focused biopharmaceutical company, today announced the closing of its previously
Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
01:43pm, Wednesday, 13'th Sep 2023
NEW YORK , Sept. 13, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for the p
Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia
08:16am, Wednesday, 13'th Sep 2023
Gastrointestinal Stromal Tumors Cells Rapidly Died Between 48 and 72 Hours After Exposure to HT-KIT. HT-KIT Shows Positive Results in AML Positive Preclinical Results of Novel HT-KIT Therapeutic Per
HT-KIT received Orphan Drug Designation from FDA for its mRNA Frame Shifting Cancer Therapeutic Hoth intends to initially target mast cell neoplasms for development of HT-KIT, which is a rare, aggress
Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa
08:12am, Wednesday, 06'th Sep 2023
78% of patients reported that their overall health had improved since starting BioLexa as compared to 22% stating that there was no change in their health, or their health was worse. DLQI found that B
Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease
08:13am, Wednesday, 09'th Aug 2023
HT-ALZ Showed Improvement on Several Tests of Cognitive Function HT-ALZ Showed Positive Benefits with Reductions in Anxiety Completed Dose Response Study Leads Hoth to Begin Formulation Development NE
Why Is Hoth Therapeutics (HOTH) Stock Up 83% Today?
11:16am, Tuesday, 06'th Jun 2023
Hoth Therapeutics (NASDAQ: HOTH ) stock is rocketing higher on Tuesday thanks to the company announcing positive results from a preclinical trial. According to a Hoth Therapeutics press release, these
Are Penny Stocks Worth the Risk? 3 Reasons Why They Could Be
06:00am, Thursday, 23'rd Feb 2023
Are penny stocks worth investing in? The post Are Penny Stocks Worth the Risk?
Why Hoth Therapeutics Shares Are Nosediving - Hoth Therapeutics (NASDAQ:HOTH)
10:59am, Friday, 30'th Dec 2022
Hoth Therapeutics Inc HOTH shares are trading lower by 21.22% to $8.44 Friday morning after the company announced a $10 million private placement priced at-the-market under Nasdaq rules.
Why Is Hoth Therapeutics (HOTH) Stock Up 24% Today?
01:12pm, Monday, 31'st Oct 2022
Hoth Therapeutics (NASDAQ: HOTH ) stock is rising higher on Monday positive results from a Phase 1 clinical trial of BioLexa. BioLexa is a treatment in development at Hoth Therapeutics for mild-to-mod
Hoth Therapeutics Announces Pipeline Presentation at the 2022 Sidoti Investor Conference
01:48pm, Friday, 12'th Aug 2022
NEW YORK , Aug. 12, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today announced the company will be presenting at the
Hoth Therapeutics Shares Surge On Encouraging Preclinical Data From Alzheimer's Program
02:37pm, Tuesday, 12'th Jul 2022
Hoth Therapeutics Inc (NASDAQ: HOTH) has announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model. HT-ALZ is therapeutic in develop
Why Hoth Therapeutics Shares Are Skyrocketing Today
11:42am, Tuesday, 12'th Jul 2022
Hoth Therapeutics Inc (NASDAQ: HOTH) shares are trading higher by 17% to $0.47 Tuesday morning after the company announced its HT-ALZ therapeutic showed cognitive improvements in an Alzheimer's Dis
